The global neprilysin market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Neprilysin is a zinc-dependent metalloprotease. It cleaves peptides at the amino side of hydrophobic residues as well as inactivates several peptide hormones such as glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. The major factor driving the growth of the market is the rising prevalence of hypertension across the globe.
According to the World Health Organization (WHO), in 2021, hypertension is a major cause of premature death globally and an estimated 1.28 billion adults aged 30 years to 79 years have hypertension with two-thirds living in low- and middle-income countries. Additionally, as per the same source, an estimated 46% of adults with hypertension are unaware that they have the condition and less than half of adults or 42% with hypertension are diagnosed and treated. Furthermore, approximately 1 in 5 adults or 21% with hypertension have it under control. Hence, the increasing prevalence of hypertension is driving the demand for neprilysin as it increases the bioavailability of natriuretic peptides (NPs), bradykinin, and substance P which results in natriuretic, vasodilatatory, and anti-proliferative effects.
To Request a Sample of our Report on Neprilysin Market: https://www.omrglobal.com/request-sample/neprilysin-market
Some major players operating in the market include Novartis International AG, Cipla Ltd., and Merck KGaA, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Novartis announced that it has received approval for Entresto (sacubitril/valsartan) from the US FDA. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan and is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Novartis International AG, Cipla Ltd., and Merck KGaA, among others
(Get 15% Discount on Buying this Report)
A full Report of Neprilysin Market is Available @ https://www.omrglobal.com/industry-reports/neprilysin-market
Global Neprilysin Market Report by Segment
By Type
- TD-0714
- Sacubitril
- PL-265
- STR-324
- LHW-090
- Others
By Application
- Acute Heart Failure
- Cancer Pain
- Hypertension
- Alzheimer’s Disease
- Other
Global Neprilysin Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
